This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

AB101

AntriaBio, Inc.

Drug Names(s): AB-101

Description: AB-101 is a once-weekly, injectable, PEGylated, microsphere-encapsulated, basal insulin formulation. The long duration of action is based on AntriaBio's proprietary technology wherein the PEGylated insulin is encapsulated in poly-lactic, poly-glycolic low-molecular weight microspheres, designed to release insulin slowly and uniformly.

Deal Structure: AntriaBio purchased the intellectual property and assets of PR Pharmaceuticals in 2013 after that company filed for Chapter 11 bankruptcy in 2008. Included in those assets was AB101.


AB101 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug